germans trias i pujol - Fundació Institut d'Investigació en Ciències de ...

Fundació Institut d'Investigació
en Ciències de la Salut
Germans Trias i Pujol
Lysek R, Schutz C, Favre S, O'Sullivan AC, Pillonel C, Krulle T, Jung PMJ, Clotet‐Codina I, Este JA, Vogel P.
Search for alpha‐glucosidase inhibitors: New N‐substituted valienamine and conduramine F‐1 derivatives.
BIOORGAN MED CHEM 2006; 14(18):6255‐6282.
IF: 2,424
Manetti F, Tintori C, Armand‐Ugon M, Clotet‐Codina I, Massa S, Ragno R, Este JA, Botta M.
A combination of molecular dynamics and docking calculations to explore the binding mode of ADS‐J1, a
polyanionic compound endowed with anti‐HIV‐1 activity.
J CHEM INF MODEL 2006; 46(3):1344‐1351.
IF: 3,423
Martinez‐Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, Chetty S, Thobakgale C, Honeyborne I, Crawford H,
Matthews P, Pillay T, Rousseau C, Mullins JI, Brander C, Walker BD, Stuart DI, Kiepiela P, Goulder P.
Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1.
J VIROL 2006; 80(7):3617‐3623.
IF: 5,341
May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F,
Fatkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M; Antiretroviral Therapy (ART) Cohort Collaboration.
HIV treatment response and prognosis in Europe and North America in the first decade of highly active
antiretroviral therapy: a collaborative analysis.
LANCET 2006 Aug 5;368(9534):451‐8
IF: 25,8
Mocroft A, Neaton J, Bebchuk J, Staszewski S, Antunes F, Knysz B, Law M, Phillips AN, Lundgren JD; EuroSIDA Study
Group; ESPRIT Study Group.
The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era.
Clin Trials 2006; 3(2):119‐32
IF:
Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, Knysz B, Antunes F, Reiss P, Lundgren JD.
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with
suppressed viremia.
AIDS 2006 May 12;20(8):1141‐50
IF: 5,632
Mocroft A, Rockstroh J, Soriano V, Kirk O, Viard JP, Caplinskas S, Gasiorowski J, Chiesi A, Phillips AN, Lundgren JD,
EuroSIDA Study Group.
Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis
C. SCAND J INFECT DIS 2006;38(11‐12):1092‐7 IF: 1,56
Molto J, Blanco A, Miranda C, Miranda J, Puig J, Valle M, DelaVarga M, Fumaz CR, Barbanoj MJ, Clotet B.
Variability in non‐nucleoside reverse transcriptase and protease inhibitor concentrations among HIV‐infected
adults in routine clinical practice.
BRIT J CLIN PHARMACO 2006; 62(5):560‐566.
IF: 2,718
Molto J, Ruiz L, Valle M, Martinez‐Picado J, Bonjoch A, Bravo I, Negredo E, Heilek‐Sneider GM, Clotet B.
Increased antiretroviral potency by the addition of enfuvirtide to a four‐drug regimen in antiretroviral‐naive, HIV‐
infected patients.
Pàgina 55/177